http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 13 Feb 2026 17:00:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26001692.html si-local-file:///var/storage/secattach/20260213/26001692.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26001692.html Fri, 13 Feb 2026 17:00:00 -0500 KZR O.23676619 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26001692.html si-local-file:///var/storage/secattach/20260213/26001692.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Stonepine+Capital+Management%2C+LLC/26001692.html Fri, 13 Feb 2026 17:00:00 -0500 KZR O.23676619 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967478.html si-local-file:///var/storage/secattach/20260209/25967478.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967478.html Mon, 09 Feb 2026 14:39:00 -0500 KZR O.23676619 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967478.html si-local-file:///var/storage/secattach/20260209/25967478.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+BML+Investment+Partners%2C+L.P./25967478.html Mon, 09 Feb 2026 14:39:00 -0500 KZR O.23676619 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54392571&amp;newsitemid=20260109889203&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=7404c2d007482c5871c43cb4d85dbfd6" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune hepatitis (AIH). </p><p> The Type C meeting will involve review of a potential global, randomized Phase 2b clinical study of zetomipzomib in patients with relapsed and refractory http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Announces+Regulatory+Update+on+Zetomipzomib+Program+in+Autoimmune+Hepatitis/25828647.html Fri, 09 Jan 2026 06:01:00 -0500 A.50100012 KZR O.07579093 O.23676619 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Avidity+Partners+Management+LP/25615100.html si-local-file:///var/storage/secattach/20251114/25615100.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Kezar+Life+Sciences%2C+++++++++++++++++++Filed+by%3A+Avidity+Partners+Management+LP/25615100.html Fri, 14 Nov 2025 13:33:00 -0500 KZR http://www.streetinsider.com/Earnings/Kezar+Life+Sciences+%28KZR%29+Misses+Q3+EPS+by+153c/25601662.html <p>Kezar Life Sciences (NASDAQ: KZR) reported Q3 EPS of ($1.53).</p><p>For earnings history and earnings-related data on Kezar Life Sciences (KZR) <a href="http://www.streetinsider.com/ec_earnings.php?q=KZR">click here</a>.</p> http://www.streetinsider.com/Earnings/Kezar+Life+Sciences+%28KZR%29+Misses+Q3+EPS+by+153c/25601662.html Thu, 13 Nov 2025 06:24:47 -0500 KZR http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kezar+Life+Sciences%2C++++++For%3A+Sep+30/25598594.html si-local-file:///var/storage/secattach/20251112/25598594.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Kezar+Life+Sciences%2C++++++For%3A+Sep+30/25598594.html Wed, 12 Nov 2025 16:22:00 -0500 KZR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kezar+Life+Sciences%2C++++++For%3A+Nov+12/25598051.html si-local-file:///var/storage/secattach/20251112/25598051.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Kezar+Life+Sciences%2C++++++For%3A+Nov+12/25598051.html Wed, 12 Nov 2025 16:08:00 -0500 KZR http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Press+Releases/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093 http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html <p> SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fkezarlifesciences.com%2F&amp;esheet=54356564&amp;newsitemid=20251112668726&amp;lan=en-US&amp;anchor=Kezar+Life+Sciences%2C+Inc&amp;index=1&amp;md5=54bb1943446bd14b8e6abf26cfb65fe4" shape="rect">Kezar Life Sciences, Inc</a>. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. </p><p> In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with relapsed and refractory autoimmune hepatitis (AIH). Kezar initiated a process to explore a full range of strategic alternatives focused on maximizing shareholder http://www.streetinsider.com/Business+Wire/Kezar+Life+Sciences+Reports+Third+Quarter+2025+Financial+Results/25597612.html Wed, 12 Nov 2025 16:01:00 -0500 A.04855241 A.50100012 KZR O.00783133 O.07579093